Cargando…

Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates

Neonatal hypoxic ischaemic (HI) injury frequently causes neural impairment in surviving infants. Our knowledge of the underlying molecular mechanisms is still limited. Protein deimination is a post-translational modification caused by Ca(+2)-regulated peptidylarginine deiminases (PADs), a group of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Sigrun, Rocha-Ferreira, Eridan, Thei, Laura, Mawjee, Priyanka, Bennett, Kate, Thompson, Paul R, Subramanian, Venkataraman, Nicholas, Anthony P, Peebles, Donald, Hristova, Mariya, Raivich, Gennadij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185393/
https://www.ncbi.nlm.nih.gov/pubmed/24762056
http://dx.doi.org/10.1111/jnc.12744
_version_ 1782337974658138112
author Lange, Sigrun
Rocha-Ferreira, Eridan
Thei, Laura
Mawjee, Priyanka
Bennett, Kate
Thompson, Paul R
Subramanian, Venkataraman
Nicholas, Anthony P
Peebles, Donald
Hristova, Mariya
Raivich, Gennadij
author_facet Lange, Sigrun
Rocha-Ferreira, Eridan
Thei, Laura
Mawjee, Priyanka
Bennett, Kate
Thompson, Paul R
Subramanian, Venkataraman
Nicholas, Anthony P
Peebles, Donald
Hristova, Mariya
Raivich, Gennadij
author_sort Lange, Sigrun
collection PubMed
description Neonatal hypoxic ischaemic (HI) injury frequently causes neural impairment in surviving infants. Our knowledge of the underlying molecular mechanisms is still limited. Protein deimination is a post-translational modification caused by Ca(+2)-regulated peptidylarginine deiminases (PADs), a group of five isozymes that display tissue-specific expression and different preference for target proteins. Protein deimination results in altered protein conformation and function of target proteins, and is associated with neurodegenerative diseases, gene regulation and autoimmunity. In this study, we used the neonatal HI and HI/infection [lipopolysaccharide (LPS) stimulation] murine models to investigate changes in protein deimination. Brains showed increases in deiminated proteins, cell death, activated microglia and neuronal loss in affected brain areas at 48 h after hypoxic ischaemic insult. Upon treatment with the pan-PAD inhibitor Cl-amidine, a significant reduction was seen in microglial activation, cell death and infarct size compared with control saline or LPS-treated animals. Deimination of histone 3, a target protein of the PAD4 isozyme, was increased in hippocampus and cortex specifically upon LPS stimulation and markedly reduced following Cl-amidine treatment. Here, we demonstrate a novel role for PAD enzymes in neural impairment in neonatal HI Encephalopathy, highlighting their role as promising new candidates for drug-directed intervention in neurotrauma. Hypoxic Ischaemic Insult (HI) results in activation of peptidylarginine deiminases (PADs) because of calcium dysregulation. Target proteins undergo irreversible changes of protein bound arginine to citrulline, resulting in protein misfolding. Infection in synergy with HI causes up-regulation of TNFα, nuclear translocation of PAD4 and change in gene regulation as a result of histone deimination. Pharmacological PAD inhibition significantly reduced HI brain damage.
format Online
Article
Text
id pubmed-4185393
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41853932014-10-06 Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates Lange, Sigrun Rocha-Ferreira, Eridan Thei, Laura Mawjee, Priyanka Bennett, Kate Thompson, Paul R Subramanian, Venkataraman Nicholas, Anthony P Peebles, Donald Hristova, Mariya Raivich, Gennadij J Neurochem Original Articles Neonatal hypoxic ischaemic (HI) injury frequently causes neural impairment in surviving infants. Our knowledge of the underlying molecular mechanisms is still limited. Protein deimination is a post-translational modification caused by Ca(+2)-regulated peptidylarginine deiminases (PADs), a group of five isozymes that display tissue-specific expression and different preference for target proteins. Protein deimination results in altered protein conformation and function of target proteins, and is associated with neurodegenerative diseases, gene regulation and autoimmunity. In this study, we used the neonatal HI and HI/infection [lipopolysaccharide (LPS) stimulation] murine models to investigate changes in protein deimination. Brains showed increases in deiminated proteins, cell death, activated microglia and neuronal loss in affected brain areas at 48 h after hypoxic ischaemic insult. Upon treatment with the pan-PAD inhibitor Cl-amidine, a significant reduction was seen in microglial activation, cell death and infarct size compared with control saline or LPS-treated animals. Deimination of histone 3, a target protein of the PAD4 isozyme, was increased in hippocampus and cortex specifically upon LPS stimulation and markedly reduced following Cl-amidine treatment. Here, we demonstrate a novel role for PAD enzymes in neural impairment in neonatal HI Encephalopathy, highlighting their role as promising new candidates for drug-directed intervention in neurotrauma. Hypoxic Ischaemic Insult (HI) results in activation of peptidylarginine deiminases (PADs) because of calcium dysregulation. Target proteins undergo irreversible changes of protein bound arginine to citrulline, resulting in protein misfolding. Infection in synergy with HI causes up-regulation of TNFα, nuclear translocation of PAD4 and change in gene regulation as a result of histone deimination. Pharmacological PAD inhibition significantly reduced HI brain damage. BlackWell Publishing Ltd 2014-08 2014-05-24 /pmc/articles/PMC4185393/ /pubmed/24762056 http://dx.doi.org/10.1111/jnc.12744 Text en © 2014 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lange, Sigrun
Rocha-Ferreira, Eridan
Thei, Laura
Mawjee, Priyanka
Bennett, Kate
Thompson, Paul R
Subramanian, Venkataraman
Nicholas, Anthony P
Peebles, Donald
Hristova, Mariya
Raivich, Gennadij
Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title_full Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title_fullStr Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title_full_unstemmed Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title_short Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates
title_sort peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (hi) in neonates
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185393/
https://www.ncbi.nlm.nih.gov/pubmed/24762056
http://dx.doi.org/10.1111/jnc.12744
work_keys_str_mv AT langesigrun peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT rochaferreiraeridan peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT theilaura peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT mawjeepriyanka peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT bennettkate peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT thompsonpaulr peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT subramanianvenkataraman peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT nicholasanthonyp peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT peeblesdonald peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT hristovamariya peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates
AT raivichgennadij peptidylargininedeiminasesnoveldrugtargetsforpreventionofneuronaldamagefollowinghypoxicischemicinsulthiinneonates